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Abstract
Aim—To develop and apply a novel genotyping method for the 9-bp exon 1 insertion/deletion
polymorphism in BDKRB2.
Materials & methods—DNA from 718 patients with heart failure was extracted using standard
methods and a region containing exon 1 of BDKRB2 was amplified with PCR. The PCR product
was separated using the Qiagen QIAxcel® capillary electrophoresis system. The bp size of the
PCR product was calculated and the genotypes determined using Qiagen BioCalculator® software.
Results—Capillary electrophoresis accurately genotyped samples with >99% call rate and 700 s
run time per row of a 96-well plate (i.e., less than 1 min per sample). The frequency of the deletion
was 49% in the Caucasian patients (n = 441) and 45% in the African–American (n = 277).
Conclusion—Capillary electrophoresis is a rapid, accurate and sensitive method for genotyping
the 9-bp exon 1 insertion/deletion polymorphism in BDKRB2.
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Cardiovascular disease (CVD) is a major public health problem. Each day >2200 Americans
die from CVD, which accounts for one out of every three deaths in the USA [1]. Current
research has focused on identifying genetic polymorphisms associated with the
predisposition, prognosis and response to drug therapy in CVD. One such CVD-relevant
gene encodes the bradykinin receptor B2 (BDKRB2). Bradykinin, through its B2 receptor,
exerts many vascular protective effects: the stimulation of microangiogenesis, inhibition of
smooth-muscle cell growth, coronary vasodilatation, increased local nitric oxide synthesis
and antithrombotic actions [2]. A common, 9-bp insertion/deletion (indel) polymorphism
exists in exon 1 of BDKRB2 (no rs identifier in the National Center for Biotechnology
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Information database of SNPs [dbSNPs]) [101]. The frequency of the deletion allele is
approximately 50% and approximately 40% in healthy Caucasians and African–Americans,
respectively [3]. The presence of the deletion results in increased gene transcription [4] and
mRNA expression [5]. The BDKRB2 indel has been associated with CVD-relevant
phenotypes such as blood pressure [3], left ventricular growth [6] and response to
antihypertensive treatment [7].
The most studied CVD-relevant indel is a 287-bp deletion in the ACE gene, and well-
established genotyping methods are available in the literature [8–10]. However because of
the small (9 bp) size of the BDKRB2 indel, rapid and accurate genotyping of this
polymorphism for large-scale CVD association studies is challenging. One currently used
method for genotyping the BDKRB2 indel is a two-step PCR followed by gel
electrophoresis; however this method is time intensive [11]. Single-step PCR followed by
gel electrophoresis has also been performed, but very long separation times are required to
reach a sensitivity which allows for the differentiation between alleles [12]. An alternative
method is PCR followed by sequencing [5]; however, sequencing indels often does not
discriminate heterozygotes, and therefore a preparation step with gel electrophoresis is
additionally required. Genotyping small indels in hundreds to thousands of patients in large-
scale CVD association studies requires rapid, automated, sensitive and accurate methods.
Unlike the methods reported in the literature, capillary electrophoresis satisfies these
requirements. Herein we report a capillary electrophoresis method for genotyping the 9-bp
indel in exon 1 of BDKRB2, and, for the first time, the frequency of this polymorphism in
Caucasian and African–American patients with heart failure.
Materials & methods
Patients
Patients with heart failure (n = 718; 441 Caucasians and 277 African–Americans) from the
United Investigators to Evaluate Heart Failure (UNITE-HF) [13] multicenter DNA
repository (UNITE-DNA) were genotyped. Patients were enrolled in UNITE-DNA from 13
outpatient specialty heart failure clinics across the USA if they had a history of heart failure
defined as dyspnea on exertion or edema due to cardiac causes. There was no left ventricular
ejection fraction requirement. The University of North Carolina at Chapel Hill (NC, USA)
has served as the coordinating center for the UNITE-DNA network since its founding in
2000. The study was approved by the institutional review boards at each of the study sites,
and informed consent was obtained from all participants prior to enrollment.
DNA sample preparation
Peripheral blood (25 ml) was drawn from each patient using ethylenediaminetetraacetic acid
tubes as an anticoagulant. Genomic DNA was extracted from peripheral blood samples
using standard methods [14]. The stock DNA concentration was determined using the
Quant-iT™ PicoGreen® dsDNA kit (Invitrogen, Molecular Probes, OR, USA). Working
stock DNA (1 ng/µl) was made by normalizing aliquots of stock DNA in molecular-grade
water (Mediatech, VA, USA) using a Biomek® 3000 laboratory automated workstation
(Beckman Coulter, CA, USA).
PCR
Based on the exon 1 9-bp indel polymorphism in BDKRB2 reported by Braun et al. [15], the
following forward and reverse primers were used: 5´-GCCCTTGAAAGATGAGCTG-3´
and 5´-AACTCCCCACGACCACAG-3´. The expected PCR product size with the insertion
allele was 275 bp and the deletion allele was 266 bp. The PCR mixture contained 10 µl of
HotStarTaq® Plus Master Mix (2×) (Qiagen, Hilden, Germany), 4 µl of Q solution (5×)
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(Qiagen), 2 µl of each primer (10 µM) and 2 µl of working stock DNA (1 ng/µl) in a final
volume of 20 µl. A DNA Engine Tetrad® 2 Peltier thermal cycler (BioRad, CA, USA) was
used with the following conditions based on Braun et al. [15]: initial incubation at 95°C for
5 min followed by 40 amplification cycles (1 min at 94°C, 1 min at 53°C and 1 min at 72°C)
and a final elongation at 72°C for 10 min.
Capillary electrophoresis
High-resolution capillary electrophoresis was performed using a QIAxcel® DNA high-
resolution gel cartridge (Qiagen)on a QIAxcel system (Qiagen), as per the manufacturer’s
instructions. A QX DNA Size Marker (Qiagen) with 17 fragment sizes ranging in size from
25 to 450 bp was used to size PCR products. A QX Alignment Marker (Qiagen), which
consisted of 15 bp and 500 bp fragments, was injected onto the cartridge with each sample.
The 0M700 method in the BioCalculator® software (Qiagen) was used for all analyses; this
corresponds to a 10 s sample injection time at 5 kV, and 700 s separation time at 3 kV. The
QIAxcel system injected 0.1 µl of 20 µl PCR products onto a cartridge for analysis. The
retention time of the PCR fragments relative to the 15-bp and 500-bp QX Alignment Marker
fragments was calculated using the BioCalculator software (Qiagen). The PCR product sizes
were then determined by comparing the retention time with the QX DNA Size Marker. The
BioCalculator software produces a digital gel image and an electropherogram for fragment
analysis.
Quality control
To ensure genotyping accuracy, the following quality control measures were performed: one
negative control per 96-well plate (i.e., water used in place of DNA); all samples without an
initial genotype call were rerun; comparison of UNITE-DNA allele frequencies to published
frequencies of the same race; repeat genotyping of 10% of samples, randomly chosen and
verification of concordance between calls; visual inspection of gel images by one individual;
visual inspection of gel images for 10% of samples selected at random by a separate
individual; and the χ2 test for deviation from the Hardy–Weinberg equilibrium. To confirm
the accuracy of our genotyping method, we obtained six DNA samples of known genotype,
which included two samples of each genotype, from an independent laboratory. These
samples were genotyped using PCR amplification followed by DNA sequencing [3].
Results
The QIAxcel (Qiagen) capillary electrophoresis system was used to genotype the 9-bp exon
1 indel in BDKRB2 in 718 patients with heart failure and genotyped in an independent
laboratory. As shown in Figure 1, the expected PCR product sizes of 275 bp for the insertion
and 266 bp for the deletion were detected, and there was 100% genotype concordance
between the six samples genotyped by an independent laboratory and our genotyping results,
indicating that our method is accurate. As shown in electropherograms produced with the
standard BioCalculator software of the QIAxcel system (Figure 2), the peaks were readily
detectable when injecting 0.1 µl of PCR product. The genotype calls were output as a .csv
file (Figure 3). This method was rapid, in which the total run time for each row (12 samples)
of a 96-well plate was 700 s (i.e., less than 1 min per sample). The initial genotype call rate
was 95.5%, and after the original failed samples were repeated, the final call rate was
99.3%. There was 100% concordance between the initial sample runs and the 10% randomly
chosen samples run a second time, indicating that the method is reproducible. The frequency
of the deletion was 49% in the Caucasian patients and 45% in the African–American (n =
441 Caucasians and n = 277 African–Americans).The genotype frequencies for each race
were in agreement with Hardy–Weinberg equilibrium (for Caucasians, χ2: 0.5, p = 0.48; for
African–Americans, χ2: 2.5, p = 0.12).
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CVD is a major public health problem, and genetic polymorphisms may contribute to the
predisposition, prognosis and response to drug therapy in CVD. Indeed, the 9-bp insetion/
deletion polymorphism in exon 1 of BDKRB2 has been associated with CVD-relevant
phenotypes in small studies [3,6,7]; however, large clinical trials are needed to confirm the
utility of this polymorphism. Current genotyping methods for this small indel are time and
labor intensive, making large-scale genotyping a challenge. However, capillary
electrophoresis is a rapid, automated, sensitive and accurate method for genotyping small
indels [16], and this has been demonstrated here for the 9-bp indel polymorphism in exon 1
of BDKRB2. Capillary electrophoresis has several advantages over currently used methods
such as gel electrophoresis: no gel-casting or staining is required; samples are loaded
automatically; minute sample volumes are required; detection of the PCR products is
automated when the fragments pass the detector in the capillary and analyzed with software
(as opposed to visual inspection of gels upon exposure to UV light); avoids handling of
hazardous materials such as ethidium bromide; and high resolution separation is achieved in
minutes [10]. These advantages greatly facilitate the use of this method for genotyping in
large-scale CVD association studies. However, convenience comes at a cost. After the
upfront cost of the QIAxcel unit, it cost approximately US$0.75 to run each sample on the
QIAxcel after DNA extraction and PCR. Therefore, as with any genotyping method, cost is
an important consideration when selecting QIAxcel capillary electrophoresis.
In addition, this is the first report of the allele frequencies for the exon 1 9-bp indel of
BDKRB2 in both Caucasian and African–American patients with heart failure. Both races
had similar frequencies (49% in the Caucasian heart failure patients and 45% in the African–
American heart failure patients), and the frequencies were similar to those reported
previously in healthy subjects (~50% and ~40% in healthy Caucasians and African–
Americans, respectively) [3].
Future perspective
In the far future, a complete genetic profile of every patient may be available to healthcare
practitioners in order to individualize each patient’s care. This eventually will be possible
because of decreasing costs, increasing coverage and improved bioinformatics capacity for
genome-wide association studies and sequencing. However, in the near future, targeted
genotyping is required for researchers to elucidate the association between functionally
implicated polymorphisms (such as indels) and clinical outcomes in complex diseases,
which require large-scale genotyping of clinical trials and cohorts. Like genome-wide
association studies and sequencing, the cost of capillary electrophoresis may also decrease,
and at that point it would completely replace traditional gel-slab electrophoresis for
genotyping indels. Currently, the only disadvantage of capillary electrophoresis over
traditional gel electrophoresis is cost.
Executive summary
Cardiovascular disease & the 9-bp insertion/deletion in exon 1 of BDKRB2
▪ Cardiovascular disease is a major public health problem.
▪ Bradykinin, through its B2 receptor (BDKRB2), exerts many vascular
protective effects.
▪ Current methods for genotyping the 9-bp insertion/deletion (indel) in exon 1
of BDKRB2 are time and labor intensive, which limits its application to
genotyping samples in large cardiovascular clinical trials.
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A novel method for genotyping the 9-bp indel in exon 1 of BDKRB2
▪ We developed and applied a robust method for genotyping the 9-bp indel in
exon 1 of BDKRB2 using the Qiagen QIAxcel® capillary electrophoresis
system in 718 patients with heart failure.
▪ This method displayed 100% genotype concordance with samples sequenced
in an independent laboratory and 10% with randomly repeated samples.
▪ A minute volume of PCR product was necessary, and the final call rate was
>99%.
Conclusion
▪ Capillary electrophoresis with a QIAxcel system is an automated, accurate,
reliable and rapid method for genotyping the BDKRB2 exon 1 indel.
▪ The frequency of the BDKRB2 exon 1 indel is similar between Caucasian and
African–American patients with heart failure and healthy subjects of matched
race.
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Figure 1. Gel image displaying expected PCR product sizes and concordance with six samples
genotyped in an independent laboratory
Lanes E01 and E02 are homozygous for the insertion, lanes E03 and E04 are heterozygous
and lanes E05 and E06 are deletion homozygotes.
†Alignment markers.
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Figure 2. Electropherograms produced by standard BioCalculator software
Electropherograms for lanes (A) E01 (homozygous for insertion), (B) E03 (heterozygous)
and (C) E05 (homozygous for deletion) are presented.
†Alignment markers.
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Figure 3. Genotype calling output
Genotype calling for lanes E01–E06 is output as a .csv file, which is displayed in Microsoft
Excel® 2010.
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